Lantheus Holdings, Inc.
General ticker "LNTH" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $4.9B (TTM average)
Lantheus Holdings, Inc. follows the US Stock Market performance with the rate: 54.3%.
Estimated limits based on current volatility of 0.2%: low 99.86$, high 100.25$
Factors to consider:
- Total employees count: 1193 (+47.6%) as of 2025
- US accounted for 94.6% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: PMF manufacturing failure, Supply chain disruptions, Regulatory and compliance, Customer payment delays, M&A integration risks
- Current price 29.6% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [44.08$, 76.92$]
- 2026-12-31 to 2027-12-31 estimated range: [41.34$, 72.47$]
Financial Metrics affecting the LNTH estimates:
- Positive: with PPE of 11.1 at the end of fiscal year the price was neutral
- Negative: 0.33 < Interest expense per share per price, % of 0.44
- Negative: negative Industry operating cash flow (median)
- Positive: 15.80 < Operating profit margin, % of 20.16
- Negative: -0.33 < Industry inventory ratio change (median), % of -0.31
- Positive: Inventory ratio change, % of -0.20 <= 0
- Negative: Investing cash flow per share per price, % of -13.87 <= -11.23
- Negative: 42.26 < Shareholder equity ratio, % of 48.93 <= 49.86
Short-term LNTH quotes
Long-term LNTH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,296.43MM | $1,542.33MM | $1,541.61MM |
| Operating Expenses | $931.79MM | $1,085.35MM | $1,230.78MM |
| Operating Income | $364.64MM | $456.98MM | $310.83MM |
| Non-Operating Income | $46.30MM | $-26.00MM | $2.96MM |
| Interest Expense | $20.02MM | $19.67MM | $19.75MM |
| R&D Expense | $77.71MM | $168.10MM | $177.31MM |
| Income(Loss) | $410.94MM | $430.98MM | $313.79MM |
| Taxes | $84.28MM | $118.53MM | $80.23MM |
| Net Income(Loss)* | $326.66MM | $312.44MM | $233.56MM |
| Stockholders Equity | $815.89MM | $1,088.01MM | $1,089.80MM |
| Inventory | $64.03MM | $68.03MM | $64.67MM |
| Assets | $1,651.15MM | $1,980.34MM | $2,227.40MM |
| Operating Cash Flow | $305.26MM | $544.75MM | $390.14MM |
| Capital expenditure | $46.55MM | $51.62MM | $36.09MM |
| Investing Cash Flow | $5.94MM | $-226.01MM | $-627.17MM |
| Financing Cash Flow | $-13.06MM | $-118.54MM | $-316.58MM |
| Earnings Per Share** | $4.79 | $4.52 | $3.46 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.